Literature DB >> 12760825

Immune Restoration Inflammatory Syndromes: The Dark Side of Successful Antiretroviral Treatment.

Matthias Stoll1, Reinhold E. Schmidt.   

Abstract

The prevalence of cellular immunodeficiency has increased due to rising use of immunosuppressive therapies and the pandemic spread of HIV infection. More recently, the introduction of highly active antiretroviral therapy (HAART) in HIV has led to significant immune reconstitution, even in patients with previously long-lasting secondary immunodeficiency. HAART reduces morbidity and mortality in HIV infection and also changes the clinical course of prevalent subclinical opportunistic infections or autoimmune diseases. Atypical inflammatory disorders develop after initiation of HAART and have been summarized as "immune reconstitution syndrome," "immune restoration disease," and "immune restoration inflammatory syndrome." However, diagnostic criteria and standards of therapy are yet to be defined. The awareness for these diseases is of increasing importance from a clinical point of view. This review summarizes the variety of immunoreconstitution disorders and describes possible diagnostic pitfalls. We also propose possible therapeutic options.

Entities:  

Year:  2003        PMID: 12760825     DOI: 10.1007/s11908-003-0083-x

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  90 in total

Review 1.  AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy.

Authors:  A E Grulich
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-01       Impact factor: 3.731

2.  Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy.

Authors:  L A Proia; S L Ngui; S Kaur; H A Kessler; G M Trenholme
Journal:  Am J Med       Date:  2000-02-15       Impact factor: 4.965

3.  CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Authors:  D Scott-Algara; J P Aboulker; C Durier; E Badell; F Marcellin; M Prud'homme; C Jouanne; V Meiffredy; F Brun-Vezinet; G Pialoux; F Raffi
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

4.  Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.

Authors:  J Gilad; A Borer; D Hallel-Halevy; K Riesenberg; M Alkan; F Schlaeffer
Journal:  Isr Med Assoc J       Date:  2001-06       Impact factor: 0.892

5.  Normalization of cytomegalovirus-specific CD4 T cells in HIV-1-infected individuals receiving antiretroviral therapy.

Authors:  Volker Grosse; Alexander Schulte; Klaus Weber; Myriam Mendila; Roland Jacobs; Reinhold E Schmidt; Hans Heiken
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

6.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

7.  Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.

Authors:  Shelley F Stone; Silvia Lee; Niamh M Keane; Patricia Price; Martyn A French
Journal:  J Infect Dis       Date:  2002-10-23       Impact factor: 5.226

8.  Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  R Lenner; Z Bregman; A S Teirstein; L DePalo
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

10.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

View more
  11 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

2.  Primary cerebral lymphomatoid granulomatosis as an immune reconstitution inflammatory syndrome in AIDS.

Authors:  Jaime Gonzalez-Valcarcel; Iñigo Corral; Carmen Quereda; Araceli Alonso-Canovas; Maria Aparicio Hernandez; Alicia de Felipe Mimbrera; Mercedes García Villanueva
Journal:  J Neurol       Date:  2010-07-27       Impact factor: 4.849

3.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

Review 4.  Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART.

Authors:  Matthias Stoll; Reinhold E Schmidt
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

5.  Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Authors:  Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

6.  HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide.

Authors:  Brian Giunta; Yuyan Zhou; Huayan Hou; Elona Rrapo; Francisco Fernandez; Jun Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 7.  [Immune restoration inflammatory syndromes].

Authors:  M Stoll; H Heiken; G M N Behrens; R E Schmidt
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

Review 8.  The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era.

Authors:  Jiqing Xu; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2008-11-19       Impact factor: 4.147

9.  Extracorporeal Membrane Oxygenation in a 29-Year-Old Man with Pneumocystis jirovecii Respiratory Failure and AIDS.

Authors:  Antonio T Hernandez Conte; David Ng; Danny Ramzy; Deanna Dilibero; Troy M LaBounty; Cyril Gaultier; Elizabeth C Behringer
Journal:  Tex Heart Inst J       Date:  2018-08-01

10.  Immune reconstitution inflammatory syndrome: A therapeutic paradox.

Authors:  Joan Felicita Samson; V Suja; K Abdul Samad; S Sankar; G K Libu
Journal:  Indian Dermatol Online J       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.